Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses

References

• Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018. NCHS Data Brief. 2020;356:1–8.
   Google Scholar
• Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013;74(4):605–613.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. J Am Med Assoc. 2017;317(9):967–968.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Liebschutz JM, Zhang F, Ross-Degnan D, Wharam JF. Opioid prescribing after nonfatal overdose and association with repeated overdose: a cohort study. Ann Intern Med. 2016;165(5):376.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
   PubMed Web of Science ®Google Scholar
• Shen K, Barrette E, Dafny LS. Treatment of opioid use disorder among commercially insured US adults, 2008-17. Health Aff (Millwood). 2020;39(6):993–1001.
   PubMed Web of Science ®Google Scholar
• Lapham G, Boudreau DM, Johnson EA, et al. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug Alcohol Depend. 2020;207:107732.
   PubMed Web of Science ®Google Scholar
• Haffajee R, Lin LA, Bohnert ASB, Goldstick J. U.S. counties with high opioid-overdose mortality and low capacity to deliver medications for opioid use disorder: an observational study. J Clin Trans Sci. 2019;3(s1):129–129.
   PubMedGoogle Scholar
• Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O 'Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19(6):35.
   PubMed Web of Science ®Google Scholar
• Wu L-T, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.
   PubMed Web of Science ®Google Scholar
• Wen H, Druss BG, Saloner B. Self-help groups and medication use in opioid addiction treatment: a national analysis. Health Aff (Millwood). 2020;39(5):740–746.
   PubMed Web of Science ®Google Scholar
• Humphreys K. Clinicians' referral and matching of substance abuse patients to self-help groups after treatment. Psychiatr Serv. 1997;48(11):1445–1449.
   PubMed Web of Science ®Google Scholar
• Gilman SM, Dermatis H, Galanter M. Methadone anonymous: a 12-step program for methadone maintained heroin addicts. Subst Abus. 2001;22(4):247–256.
   PubMedGoogle Scholar
• Ronel N, Gueta K, Abramsohn Y, Caspi N, Adelson M. Can a 12-step program work in methadone maintenance treatment? Int J Offender Ther Comp Criminol. 2011;55(7):1135–1153.
   PubMed Web of Science ®Google Scholar
• Weinstein ZM, Kim HW, Cheng DM, et al. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65–70.
   PubMed Web of Science ®Google Scholar
• Saloner B, Daubresse M, Caleb Alexander G. Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Med Care. 2017;55(7):669–676.
   PubMed Web of Science ®Google Scholar
• Monico LB, Gryczynski J, Mitchell SG, et al. Buprenorphine treatment and 12-step meeting attendance: Conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89–95.
   PubMed Web of Science ®Google Scholar
• White W. Narcotics Anonymous and the Pharmacotherapeutic Treatment of Opioid Addiction in the United States. Philadelphia: Philadelphia Department of Behavioral Health and Intellectual disAbility Services, Great Lakes Addiction Technology Transfer Center; 2011.
   Google Scholar
• White WL, Campbell MD, Shea C, Hoffman HA, Crissman B, Dupont RL. Coparticipation in 12-step mutual aid groups and methadone maintenance treatment: a survey of 322 patients. J Groups Addict Recover. 2013;8(4):294–308.
   Google Scholar
• Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29(2):95–106.
   PubMed Web of Science ®Google Scholar
• White WL. Addiction recovery: Its definition and conceptual boundaries. J Subst Abuse Treat. 2007;33(3):229–241.
   PubMed Web of Science ®Google Scholar
• Terry Furst R. Diffusion and diversion of suboxone: an exploration of illicit street opioid selling. J Addict Dis. 2014;33(3):177–186.
   PubMed Web of Science ®Google Scholar
• Harris M, Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of 'generous constraints. Int J Drug Policy. 2013;24(6):e43–50.
   PubMedGoogle Scholar
• Schuman‐Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013;22(6):574–580.
   PubMed Web of Science ®Google Scholar
• Duffy P, Baldwin H. The nature of methadone diversion in England: a Merseyside case study. Harm Reduct J. 2012;9:3.
   PubMed Web of Science ®Google Scholar
• Johanson CE, Arfken CL, di Menza S, Schuster CR. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012;120(1-3):190–195.
   PubMed Web of Science ®Google Scholar
• Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Rev. 2011;4:28–41.
   Google Scholar
• Maxwell JC. Diversion and Abuse of Buprenorphine: A Brief Assessment of Emerging Indicators. Final report. Submitted to the Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment. Submitted by JBS International, Inc; 2006.
   Google Scholar
• Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–574.
   PubMed Web of Science ®Google Scholar
• Galanter M, Seppala M, Klein A. Medication-assisted treatment for opioid dependence in Twelve Step–oriented residential rehabilitation settings. Subst Abuse. 2016;37(3):381–383.
   Google Scholar
• Klein AA, Seppala MD. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: feasibility and initial results. J Subst Abuse Treat. 2019;104:51–63.
   PubMed Web of Science ®Google Scholar
• Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36(6):584–589.
   PubMed Web of Science ®Google Scholar
• Ducharme LJ, Knudsen HK, Roman PM. Trends in the adoption of medications for alcohol dependence. J Clin Psychopharmacol. 2006;26 Suppl 1:S13–S19.
   PubMed Web of Science ®Google Scholar
• Roman PM, Abraham AJ, Rothrauff TC, Knudsen HK. A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2010;38 Suppl 1:S44–S52.
   PubMed Web of Science ®Google Scholar
• White WL. Slaying the Dragon: The History of Addiction Treatment & Recovery in America. USA: Chestnut Health Systems/Lighthouse Institute; 1998.
   Google Scholar
• Kennedy-Hendricks A, Levin J, Stone E, Mcginty EE, Gollust SE, Barry CL. News media reporting on medication treatment for opioid use disorder amid the opioid epidemic. Health Aff (Millwood). 2019;38(4):643–651.
   PubMed Web of Science ®Google Scholar
• U.S. Public Health Service. Facing Addiction in America: The Surgeon General's Spotlight on Opioids. 2018. Washington, D.C.: U.S. Public Health Service.
   Google Scholar
• Christie C, Baker C, Cooper R, Kennedy P, Madras B, Bondi P. The president's commission on combating drug addiction and the opioid crisis. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-1-2017.pdf. Published November 1, 2017. Accessed January 16, 2020.
   Google Scholar
• Crenshaw K. Mapping the margins: Intersectionality, identity politics, and violence against women of color. Stanford Law Rev. 1991;43(6):1241–1299.
   Google Scholar
• Madden EF. Intervention stigma: how medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324–331.
   PubMed Web of Science ®Google Scholar
• Hatcher AE, Mendoza S, Hansen H. At the expense of a life: race, class, and the meaning of buprenorphine in pharmaceuticalized "care". Subst Use Misuse. 2018;53(2):301–310.
   PubMed Web of Science ®Google Scholar
• Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357.
   PubMed Web of Science ®Google Scholar
• Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–1907.
   PubMed Web of Science ®Google Scholar
• Nassaji H. Qualitative and descriptive research: data type versus data analysis. Lang Teach Res. 2015;19(2):129–132.
   Web of Science ®Google Scholar
• Dedoose Version 8.0.35, Web Application for Managing, Analyzing, and Presenting Qualitative and Mixed Method Research Data In. Los Angeles, CA: SocioCultural Research Consultants, LLC; 2018.
   Google Scholar
• Iterative Categorization (Ic): A Systematic Technique for Analysing Qualitative Data - POWERPOINT 2017.
   Google Scholar
• Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683–1694.
   PubMed Web of Science ®Google Scholar
• O'Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: A systematic review. PLoS One. 2020;15(5):e0232086.
   PubMed Web of Science ®Google Scholar
• Martin SA, Chiodo LM, Wilson A. Retention in care as a quality measure for opioid use disorder. Subst Abus. 2019;40(4):453–458.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22–35.
   PubMed Web of Science ®Google Scholar
• Goffman E. Stigma: Notes on the Management of Spoiled Identity. New York: Simon and Schuster; 1963.
   Google Scholar
• Jiao S, Bungay V. Intersections of stigma, mental health, and sex work: how Canadian men engaged in sex work navigate and resist stigma to protect their mental health. J Sex Res. 2019;56(4-5):641–649.
   PubMed Web of Science ®Google Scholar
• Ginter W. Methadone anonymous and mutual support for medication-assisted recovery. J Groups Addict Recover. 2012;7(2-4):189–201.
   Google Scholar
• Beck A, Forbes E, Baker A, et al. Systematic review of SMART recovery: outcomes, process variables, and implications for research. Psychol Addict Behav. 2017;31(1):1–20.
   PubMed Web of Science ®Google Scholar
• Horvath AT, Yeterian J. SMART recovery: self-empowering, science-based addiction recovery support. J Groups Addict Recover. 2012;7(2-4):102–117.
   Google Scholar
• O’Sullivan D, Blum JB, Watts J, Bates JK. SMART recovery: continuing care considerings for rehabilitation counselors. Rehabil Couns Bull. 2015;58(4):203–216.
   Web of Science ®Google Scholar
• Zemore SE, Kaskutas LA, Mericle A, Hemberg J. Comparison of 12-step groups to mutual help alternatives for AUD in a large, national study: differences in membership characteristics and group participation, cohesion, and satisfaction. J Subst Abuse Treat. 2017;73:16–26.
   PubMed Web of Science ®Google Scholar
• Zemore SE, Lui C, Mericle A, Hemberg J, Kaskutas LA. A longitudinal study of the comparative efficacy of Women for Sobriety, LifeRing, SMART Recovery, and 12-step groups for those with AUD. J Subst Abuse Treat. 2018;88:18–26.
   PubMed Web of Science ®Google Scholar
• Andraka-Christou B. What is treatment for opioid addiction in problem-solving courts? A study of 20 Indiana drug & veterans courts. CRCL. 2017;13:189–254.
   Google Scholar
• Lee HS, Engstrom M, Petersen SR. Harm reduction and 12 steps: Complementary, oppositional, or something in-between? Subst Use Misuse. 2011;46(9):1151–1161.
   PubMed Web of Science ®Google Scholar
• Evans AC, White WL, Lamb R. The Role of Harm Reduction in Recovery-Oriented Systems of Care: The Philadelphia Experience. Florida, USA: William White Papers.
   Google Scholar